sunitinib
pfizer
['sunitinib']
malkin #aacr23 results of ph ii trials of sunitinib in children with pn: approved in can, showed 26/50 (56%) durable response. partial response 68%.
Business development, marketing and sales professional in the life sciences, cancer diagnostics, and genomics fields. Blog: https://t.co/IeMzCogxlt. Opinions are my own.